The field of research in bladder cancer has seen significant advances in recent years. Next-
generation sequencing has identified the genes most mutated in bladder cancer. This …

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Molecular characterization of cell types using single-cell transcriptome sequencing is
revolutionizing cell biology and enabling new insights into the physiology of human organs …

Background Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with
heterogeneous clinical outcomes. Several molecular classifications have been proposed …

Bladder cancer is a highly prevalent disease and is associated with substantial morbidity,
mortality and cost. Environmental or occupational exposures to carcinogens, especially …

Background An early report on the molecular subtyping of muscle-invasive bladder cancer
(MIBC) by gene expression suggested that response to neoadjuvant chemotherapy (NAC) …

Urothelial carcinoma of the bladder comprises two long-recognized disease entities with
distinct molecular features and clinical outcome. Low-grade non-muscle-invasive tumours …

Background FGFR3-altered urothelial cancer (UC) correlates with a non-T cell-inflamed
phenotype and has therefore been postulated to be less responsive to immune checkpoint …

Cytotoxic chemotherapy is effective in debulking tumour masses initially; however, in some
patients tumours become progressively unresponsive after multiple treatment cycles …

Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with widely
different outcomes. We performed a comprehensive transcriptional analysis of 460 early …